Top Tech Companies (2,068)
Don't see your company?
Create a company profile
Vanda Pharmaceuticals (NASDAQ: VNDA) is a biopharmaceutical company focused on the development and commercialization of products for the
Vivex Biomedical is a biomedical company developing implant technology and stem cell therapies.
Boost Biomes is using the powerful social networks among microbes to provide novel, sustainable solutions to feed and heal people everywhere. Our technology differentiator is the development of a causal understanding of microbial interactions powerful enough to allow the rational construction of designer functional consortia. Our first products seek to reduce the enormous waste in agricultural products due to crop loss to fungal pests in the field and post-harvest. There is significant need for new biological, organic, safe biopesticides for crops; current chemical products have many challenges, including regulatory burden for growers and safety concerns of consumers.
Mobius Therapeutics is an early-stage venture focused on ophthalmic surgery solutions.
The Atlanta Biological brand of serum & media products is now rebranded as R&D Systems. The product quality, selection & catalog numbers will remain the same.
Sharps Compliance, Inc., based in Houston, Texas, is a leading developer and provider of superior solutions for improving safety
Sepax Technologies, Inc., is Delaware based leading chromatography product manufacturer and service provider specializing in biological separation areas. We offer unique ranges of HPLC columns for bioanalytical characterization and testing, as well as process media for downstream process and purification of MAb, BsAb, ADC, Proteins, AAV, VLP, DNA, RNA, and various biologic samples. Sepax has a full portfolio of beads technology platforms, linker and organic synthesis chemistry, as well protein chemistry in different stages of R&D and production pipelines to support the various needs of biopharmaceutical industry and customers. Check out our website for more information www.sepax-tech.com
Salutaris Medical Devices develops ophthalmic treatment for wet age-related macular degeneration.
Peli BioThermal offers the widest range of temperature-controlled, thermally-protected packaging and service solutions to the global life sciences industry. The company’s products ensure that delicate biological materials arrive intact and effective, despite exterior environments. Peli BioThermal is dedicated to developing innovative products designed to fulfil the complex needs of the global life sciences industry. The company’s customers benefit from its extensive expertise in ensuring that temperature stability is maintained throughout the distribution chain. The company also offers an innovative Rental program, Credo on Demand. Featuring Credo Cargo and Credo Xtreme bulk shippers, it is ideal for short term bulk shipments, available Globally. Also on offer for long term lease options is the Credo on Reserve program. For more information, visit http://www.pelibiothermal.com. Peli BioThermal’s key products and services include: - Credo™ Cube – Reusable parcel shippers offering long durations and excellent thermal protection. - Credo Xtreme™ - Reusable bulk shipper available in half and full pallet sizes - CoolGuard™ PCM- a range of single-use parcel shippers, utilising phase change materials - CoolGuard™ Advance- Our Award winning range of high performance single-use parcel shippers, utilising advanced insulation and phase change materials - NanoCool - Innovative, Push button activated, single use shipper. - CoolPall™ Vertos - Our high performance single-use bulk shipper, designed as a flat pack, easily assembled product. - CoolPall™ Flex - innovative, highly customisable bulk shipper, available in 3 heights and 2 footprints, ISO / EURO - Credo on Demand™ - Our high performance, cost-effective rental programme for temperature controlled pallet shipments. In addition, customer bespoke designs are also possible developed with clients utilising our dedicated packaging engineering and thermal testing team.
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
Maravai LifeSciences enables the miracles of science and improves the human condition through its portfolio of market-leading companies and proprietary technologies. Biomedical innovation is dependent on a reliable supply of reagents in the fields of nucleic acid production and biologics safety testing. From inventive startups to many of the world's leading biopharma, vaccine, diagnostics and cell and gene therapy companies, customers turn to Maravai to solve their complex discovery challenges and help them streamline and scale from research through clinical trials. TriLink BioTechnologies is a global leader in RNA synthesis and scale up, including mRNA production, yield-enhancing proprietary CleanCap® mRNA capping technology, and CDMO services ranging from research to GMP grades. Glen Research leads in specialty reagents for DNA and RNA oligonucleotide synthesis for a broad range of applications. Cygnus Technologies developed the market for bioprocess impurity detection, process-related impurity analytics and viral clearance prior to human trials, regulatory approval and commercial release. Maravai holds a number of patents and offers innovative products and services including CleanCap®, CleanAmp®, GMPLink™, Antibody Affinity Extraction™ (AAE™), EndonucleaseGTP®, PROTEIN A MIX-N-GO™, MockV™, Sterling™, Glen Pak™, Glen Gel-Pak™, Poly-Pak™. Maravai's portfolio companies are ISO-9001:2015 certified and have earned hundreds of thousands of citations in peer-reviewed scientific publications. Founded in 2014 and headquartered in San Diego, Maravai LifeSciences is online at www.maravai.com.
InduPro is bringing life-changing therapies to patients through novel cell-surface platform technologies. We are defining and manipulating protein interactions beyond natural signaling paradigms. InduPro platforms, integrate inherent protein proximity at the cell surface with the ability to manipulate protein pairings via induced protein proximity to create novel signaling pathways and logic gates.
BioAi Health is a leading provider of cutting-edge technologies and services, offering scalable solutions for companies of all sizes. Our platform technology integrates complex data sets from translational studies and clinical trials. We have the capability to develop machine learning models on multi-omic data that can help predict patient response to therapy & drug resistance Founded by a group of friends who started by scribbling their ideas on a piece of paper, today we offer smart, innovative services to dozens of clients worldwide. Our team of experts has a proven track record in developing strategic partnerships with the Pharma industry and solving major challenges in R&D
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs. Learn more: www.AjiBio-Pharma.com
CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected. We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population. CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category. CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.
At Invisible Sentinel, we develop first in class, next generation technologies for a safer food supply.
ATUM, formerly DNA2.0, offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering and production. ATUM exploits the dependence of biological activity on well-designed sequences. ATUM’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. By collaborating with our clients, ATUM accelerates breakthroughs and moves research further faster.
Microarrays develops products that microarray data for applications in analyte testing, diagnostics, and personalized medicine.
Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care. More than 800,000 patients across the world are impacted by Ortho’s tests each day. Because Every Test is a Life, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate, and reliable. Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs. From launching the first product to determine Rh+ or Rh- blood type, developing the world’s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years. The company is powered by Ortho Care, an award-winning, holistic service and support program that ensures best-in-class technical, field and remote service and inventory support to laboratories in more than 130 countries and territories around the globe.
